In a pharma business deal, Proteus Digital Health and Otsuka Pharmaceutical have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize a new category of medicines.
Under the pharma business agreement, Proteus and Otsuka have entered an exclusive collaboration to develop commercial products in two defined therapeutic areas of high unmet medical need.
Otsuka has also been granted a non-exclusive license to utilize Proteus technology in its clinical research and development activities as a part of this pharma business agreement.
Financial terms of the pharma business agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity